Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
GastrinomaGlucagonoma8 moreThis phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Carcinoid TumorMetastatic Carcinoid Tumor1 moreThis phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary site (place where they started) to other places in the body (metastatic). Nintedanib may stop the growth of tumor cells by slowing or stopping a certain type of receptor called vascular endothelial growth factor receptor (VEGFR) from attaching to its target. This may stop the growth of neuroendocrine tumors by blocking the growth of new blood vessels necessary for tumor growth.
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Carcinoid SyndromeThe primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Carcinoid TumorMalignant Carcinoid SyndromeThe purpose of this study was to evaluate whether everolimus 10 mg / day added to treatment with depot octreotide prolongs progression free survival compared to treatment with octreotide alone in patients with advanced carcinoid tumor.
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
GastrinomaGlucagonoma19 moreRATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus together with vatalanib may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and vatalanib in treating patients with advanced solid tumors.
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients...
Carcinoid TumorAcromegalyThis study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
Carcinoid TumorsNeuroendocrine TumorsThis is a research study looking at the effect of 5-Hydroxy Tryptophan (5-HTP) on urine excretion of 5-Hydroxyindolacetic acid (5-HIAA). 5-HTP is a common over the counter product that is sold in natural food stores and via the Internet. Increased levels of 5-HIAA in the urine can be found in a specific type of cancer, called carcinoid tumor. This study will examine the effect of oral 5-HTP intake on 5-HIAA excretion. Understanding this effect may help to determine which tests should be done in a patient with increased 5-HIAA excretion who's also taking 5-HTP.
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Metastatic Gastrointestinal Carcinoid TumorPulmonary Carcinoid Tumor2 moreThis phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
GastrinomaGlucagonoma7 moreThis phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal...
Extrahepatic Bile Duct CancerGastric Cancer4 moreRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person recover from the side effects of chemotherapy. Combining chemotherapy with interferon alfa may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and interferon alfa followed by filgrastim in treating patients who have gastrointestinal tract cancer.